Ruza Arsenic
Overview
Explore the profile of Ruza Arsenic including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
653
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schossig P, Coskun E, Arsenic R, Horst D, Sehouli J, Bergmann E, et al.
Int J Mol Sci
. 2023 Feb;
24(3).
PMID: 36768616
Adoptive T cell-receptor therapy (ACT) could represent a promising approach in the targeted treatment of epithelial ovarian cancer (EOC). However, the identification of suitable tumor-associated antigens (TAAs) as targets is...
2.
Merola E, Perren A, Rinke A, Zerbi A, McNamara M, Arsenic R, et al.
J Neuroendocrinol
. 2022 Oct;
34(10):e13193.
PMID: 36306194
Neuroendocrine neoplasms (NENs) present with advanced disease at diagnosis in up to 28% of cases, precluding the possibility of curative-intent surgery. Histopathological heterogeneity of this disease can be observed inter-individually...
3.
Busse A, Mochmann L, Spenke C, Arsenic R, Briest F, Johrens K, et al.
Cancers (Basel)
. 2020 Nov;
12(11).
PMID: 33228231
Checkpoint inhibitors have shown promising results in a variety of tumors; however, in neuroendocrine tumors (NET) and neuroendocrine carcinomas (NEC), low response rates were reported. We aimed herein to investigate...
4.
Pape U, Kasper S, Meiler J, Sinn M, Vogel A, Muller L, et al.
Cancers (Basel)
. 2020 Oct;
12(11).
PMID: 33121007
CAP7.1 is a novel topoisomerase II inhibitor, converted to active etoposide via carboxylesterase 2 (CES2), with signals of efficacy in treatment-refractory solid tumours. In a Phase II trial, 27 patients...
5.
Merola E, Dal Buono A, Denecke T, Arsenic R, Pape U, Jann H, et al.
Pancreas
. 2020 Jul;
49(7):912-917.
PMID: 32658073
Objectives: The objective of this study was to investigate the efficacy and tolerability of 5-fluorouracil-oxaliplatin (FOLFOX) in advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs). Methods: Retrospective analysis of consecutive 72 advanced GEP-NENs...
6.
Claussen F, Gassner J, Moosburner S, Wyrwal D, Nosser M, Tang P, et al.
PLoS One
. 2020 Jul;
15(7):e0235635.
PMID: 32614897
Background: Normothermic ex vivo liver perfusion (NEVLP) is a promising strategy to increase the donor pool in liver transplantation. Small animal models are essential to further investigate questions regarding organ...
7.
Merola E, Falconi M, Rinke A, Staettner S, Krendl F, Partelli S, et al.
Am J Surg
. 2020 Mar;
220(2):284-289.
PMID: 32209239
Background: Stage IV gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NENs) G3 are the NENs with the worst prognosis. According to ENETS guidelines, platinum-based chemotherapy is the standard treatment for this population. Surgery is...
8.
Merola E, Rinke A, Partelli S, Gress T, Andreasi V, Kollar A, et al.
Ann Surg Oncol
. 2019 Nov;
27(5):1348-1355.
PMID: 31720931
Background: While platinum-based chemotherapy represents the standard treatment for advanced grade 3 (G3) neuroendocrine neoplasms (NENs) according to the European Neuroendocrine Tumor Society guidelines, the role of radical-intended surgery in...
9.
Wagner A, Arsenic R, David M, Sehouli J, Vidosavljevic D, Rohr I
Med Glas (Zenica)
. 2019 Oct;
17(1):86-91.
PMID: 31663322
Aim To present diagnostic and therapeutic possibilities for genital and peritoneal tuberculosis, mimicking to other pathological conditions, mainly, ovarian cancer. Methods Transabdominal and transvaginal ultrasound, computerized tomography, Ca125 and HE...
10.
Merola E, Prasad V, Pascher A, Pape U, Arsenic R, Denecke T, et al.
Neuroendocrinology
. 2019 Sep;
110(6):517-524.
PMID: 31484182
Background: Peritoneal carcinomatosis (PC) can affect the quality of life of patients with gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NENs). Peritoneal disease control by medical therapies in these patients has been poorly investigated...